Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 16 |
| Active Pipeline (Recruiting Now) | 2 (1) |
| Completed vs Stopped Early | 13 / 1 (6.3%) |
| Median Closed Actual Enrollment | 44 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 1 (1 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Vanderbilt University Medical Center | Nashville, TN | 5 |
| Universitätsklinikum Bonn | Bonn, Bonn | 5 |
| Charité Universitätsmedizin Berlin | Berlin | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT07197944 | Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Zealand Pharma Interactive Dossier, benchmark peers in Gastroenterology, Hepatology, and Renal, or review the Healthcare Price & Patent Cliff Crosswalk.